期刊文献+

口服抗凝药物治疗管理路径专家共识

Expert consensus on the medication therapy management pathway of oral anticoagulant drugs
原文传递
导出
摘要 为更好地规范和优化口服抗凝药物的治疗管理,提高患者的治疗效果和生活质量,由首都医科大学附属北京安贞医院牵头,邀请了全国31家医疗机构的药学和医学专家共同制订了《口服抗凝药物治疗管理路径专家共识》。本共识紧密围绕口服抗凝药物治疗管理的全过程进行阐述,包括信息收集、适应证与禁忌证的评估、血栓和出血风险评估、药物选择与剂量调整、计划实施及后续跟踪随访等,以期为规范管理服用口服抗凝药物的患者提供参考。 To enhance the standardization and optimization of therapeutic management for oral anticoagulant drugs,ultimately improving patients'treatment outcomes and quality of life,Beijing Anzhen Hospital,affiliated with Capital Medical University,spearheaded an initiative by inviting pharmaceutical and medical experts from 31 medical institutions nationwide to jointly formulate the"Expert consensus on the medication therapy management pathway of oral anticoagulant drugs".This consensus comprehensively covers the entire process of managing oral anticoagulant therapy,including information collection,evaluation of indications and contraindications,assessment of thrombosis and bleeding risks,drug selection and dosage adjustment,plan implementation,as well as follow-up,with the aim of providing a reference for managing patients undergoing oral anticoagulant therapy.
作者 《口服抗凝药物治疗管理路径专家共识》编写组 林阳 彭文星 Writing committee of expert consensus on the medication therapy management Pathway of Oral anticoagulant drugs
出处 《临床药物治疗杂志》 2024年第9期1-23,共23页 Clinical Medication Journal
基金 国家重点研发计划精准医学研究重点专项(2017YFC0908801)。
关键词 共识 口服抗凝药物 药物治疗管理 路径 consensus oral anticoagulant drugs medication therapy management pathway
  • 相关文献

参考文献11

二级参考文献58

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2王志伟,于洪涛,杨晓涵,郭建洲,陈长春,姬尚义.主动脉机械瓣膜置换术后低强度抗凝研究[J].中华实验外科杂志,2007,24(5):602-603. 被引量:4
  • 3陆芸,马宝通,郭若霖,张建国,吴英华,庞贵根,辛景义,叶伟胜,邹玉安,王毅,董强,王学谦,Kerry H,Paul C,John F.骨科创伤患者深静脉血栓危险因素的研究[J].中华骨科杂志,2007,27(9):693-698. 被引量:244
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.

共引文献1263

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部